Clinical Trials
Ascletis Completes U.S. Phase IIa Enrollment for Once-Monthly ASC30 GLP-1 Depot Therapy in Obesity
The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) d...
October 20, 2025 | News
Aurion Biotech Data Supports Advancing High-Dose AURN001 Regenerative Cell Therapy to Phase 3 Trial in 2026
Data strongly supports advancing high dose AURN001 regenerative cell therapy for patients with corneal endothelial disease to pivotal Phase 3 trial in H1...
October 20, 2025 | News
Daiichi Sankyo and AstraZeneca’s DATROWAY Combination Delivers 68.2% Response and 95.5% Disease Control in First-Line Metastatic Urothelial Cancer
A confirmed objective response rate of 68.2% and a disease control rate of 95.5% was observed with Daiichi Sankyo and AstraZeneca’s DATROWAY in c...
October 20, 2025 | News
Merck Presents Longer-Term Phase 3 Data Showing Pimicotinib Achieves 76.2% Objective Response Rate in TGCT
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2% Global Phase 3 MANEUVER study de...
October 20, 2025 | News
PeptiDream, PDRadiopharma, and Curium Launch Registrational Phase 2 Trial in Japan for 64Cu-PSMA-I&T Targeting Prostate Cancer
PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter "PeptiDream")(Tokyo: 4587), PDRadiopharm...
October 17, 2025 | News
Jacobio Pharma Partners with Oceanpine Capital in RMB 200 Million Equity Deal for Cardiovascular Research Subsidiary
Jacobio Pharma announced that its subsidiary, Beijing Jacobio Pharmaceuticals Co., Ltd. ("Beijing Jacobio"), has entered into a Capital Increase and Equity...
October 16, 2025 | News
SK Bioscience Files Clinical Trial Application in Australia for GBP511 Universal Coronavirus Vaccine
Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses Phase 1/2 study to enroll ~500 healthy adults, with topline results e...
October 16, 2025 | News
Ascletis’ Denifanstat (ASC40) Achieves Phase III Success in Moderate-to-Severe Acne Vulgaris
Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulga...
October 15, 2025 | News
Clover Biopharmaceuticals Reports Promising Phase I Results for RSV+hMPV±PIV3 Combination Vaccines
Results indicate potential best-in-class RSV+hMPV±PIV3 combination vaccines, with the potential ability to re-vaccinate individuals previously...
October 15, 2025 | News
Ascletis Selects ASC35 as Once-Monthly, Dual GLP-1/GIP Peptide Agonist Candidate for Obesity Treatment
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, whic...
October 14, 2025 | News
GC Biopharma Secures Global CMO Rights for Curevo’s Recombinant Shingles Vaccine
GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced that it has signed an agreement with Curevo Vaccine to secure contract manufa...
October 14, 2025 | News
Anthony Elgamal: Redefining First-Line Treatment in EGFR-Mutated Lung Cancer
BioPharma APAC speaks with Anthony Elgamal, Vice President of Oncology, Johnson & Johnson Innovative Medicine Asia Pacific, on th...
October 13, 2025 | Expert Insight
Henlius’ HANSIZHUANG Meets Primary Endpoint in Phase 3 Gastric Cancer Trial
The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Applicati...
October 13, 2025 | News
Renalys Pharma Completes Primary Endpoint Data Collection in Phase III Sparsentan Trial for IgA Nephropathy
Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced that it has completed data collection for the primary endpoint in the Phase I...
October 13, 2025 | News
Most Read
- Top 25 Biotech & Biopharma Leaders in Sustainable Innovation, 2025
- China’s Biopharma Dealmaking Surges in H1 2025, Driven by Record Licensing and Oncology Focus
- Chikungunya in China: How a “Forgotten” Arbovirus Found the Perfect Storm
- How Innovation Gaps in Biopharma Raise New Safety Concerns
- Smart Implants and the Future of Musculoskeletal Injury Treatment
- How Ethical Gaps in Psychiatry Could Undermine Biopharma Progress
- The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific
- Using NLP-Driven Decision Support in Emergency Health Assistance
- Taiwan Steps Into the Global Spotlight With a New Cancer Therapy
- The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety
- The Importance of a Patient’s Mental Health During Clinical Trials
Bio Jobs
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Avantor’s New CEO Ligner Aims to Unlock Global Potential and Deliver Shareholder Value
- AstraZeneca Commits $50 Billion to U.S. Expansion by 2030 in Biggest-Ever Global Investment
- Thermo Fisher, SAMRC, and South Africa’s Department of Science and Innovation Launch CATIR to Nurture Next-Gen Scientists
- Cube Biotech Appoints Former Sartorius CEO Dr. Joachim Kreuzburg to Board of Directors
- FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut
- WuXi XDC Completes Mechanical Build of Singapore Bioconjugate Manufacturing Hub
News
Editor Picks
